Effects of combined therapy of imeglimin and hypolipidemic agents on metabolic parameter in patients with type 2 diabetes

Effects of combined therapy of imeglimin and hypolipidemic agents on metabolic parameter in patients with type 2 diabetes - Effects of combined therapy of imeglimin and hypolipidemic agents on metabolic parameter in patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053539

Enrollment

100

Registered

2024-02-05

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

The patients with type 2 diabetes are treated with imeglimin (2000 mg/day) and hypolipidemic agent (1-2 mg/day pitavastatin or 2.5-5 mg/day rosuvastatin) for 12 months The patients with type 2 diabete

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemoglobin A1c level: 6.5-11.5%

Exclusion criteria

Exclusion criteria: eGFR: less than 45 mL/min/1.73m2

Design outcomes

Primary

Measure	Time frame
Body weight, serum lipids, and liver function marker	—

Secondary

Measure	Time frame
Hemoglobin A1c level	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

kusunoki@tonyo.jp052-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026